Barclays PLC Increases Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Barclays PLC boosted its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 128.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 154,297 shares of the biopharmaceutical company’s stock after buying an additional 86,677 shares during the quarter. Barclays PLC owned approximately 0.26% of Vanda Pharmaceuticals worth $722,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of VNDA. ClearAlpha Technologies LP lifted its holdings in shares of Vanda Pharmaceuticals by 50.0% in the 3rd quarter. ClearAlpha Technologies LP now owns 60,000 shares of the biopharmaceutical company’s stock worth $281,000 after acquiring an additional 20,000 shares during the last quarter. Verition Fund Management LLC lifted its stake in Vanda Pharmaceuticals by 7.8% in the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 2,927 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Vanda Pharmaceuticals by 1,184.6% in the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 57,393 shares during the last quarter. FMR LLC boosted its position in Vanda Pharmaceuticals by 25.9% during the third quarter. FMR LLC now owns 149,739 shares of the biopharmaceutical company’s stock valued at $702,000 after buying an additional 30,802 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 0.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after buying an additional 3,473 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Stock Up 0.2 %

Shares of Vanda Pharmaceuticals stock opened at $4.79 on Wednesday. The company’s fifty day simple moving average is $4.86 and its two-hundred day simple moving average is $5.15. Vanda Pharmaceuticals Inc. has a 12-month low of $3.46 and a 12-month high of $6.75. The firm has a market cap of $279.30 million, a PE ratio of -17.11 and a beta of 0.76.

Insider Buying and Selling

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the transaction, the director now owns 44,857 shares in the company, valued at $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.90% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. StockNews.com started coverage on Vanda Pharmaceuticals in a research note on Friday, December 27th. They issued a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report on Monday, December 23rd.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.